Id: acc0512
Group: 1sens
Protein: Smad2
Gene Symbol: SMAD2
Protein Id: Q15796
Protein Name: SMAD2_HUMAN
PTM: phosphorylation
Site: Ser467
Site Sequence: SPSVRCSSMS-----------
Disease Category: Cancer
Disease: Breast Cancer
Disease Subtype: TNBC
Disease Cellline: MDA-MB-231
Disease Info:
Drug: Nafamostat mesilate(NM)
Drug Info: "Nafamostat mesilate (NM) is a broad-spectrum serine protease inhibitor used primarily as an anticoagulant during extracorporeal circulation procedures, such as blood purification, due to its short half-life and rapid metabolism without affecting platelet function or metabolic processes. "
Effect: modulate
Effect Info: "NM inhibits TGFbeta-stimulated Smad2 phosphorylation and serum-stimulated ERK phosphorylation, thereby inhibiting the cell growth and metastasis of TNBC cells."
Note: site unclear
Score: 4.0
Pubmed(PMID): 29196918
Sentence Index:
Sentence:

Sequence & Structure:

MSSILPFTPPVVKRLLGWKKSAGGSGGAGGGEQNGQEEKWCEKAVKSLVKKLKKTGRLDELEKAITTQNCNTKCVTIPSTCSEIWGLSTPNTIDQWDTTGLYSFSEQTRSLDGRLQVSHRKGLPHVIYCRLWRWPDLHSHHELKAIENCEYAFNLKKDEVCVNPYHYQRVETPVLPPVLVPRHTEILTELPPLDDYTHSIPENTNFPAGIEPQSNYIPETPPPGYISEDGETSDQQLNQSMDTGSPAELSPTTLSPVNHSLDLQPVTYSEPAFWCSIAYYELNQRVGETFHASQPSLTVDGFTDPSNSERFCLGLLSNVNRNATVEMTRRHIGRGVRLYYIGGEVFAECLSDSAIFVQSPNCNQRYGWHPATVCKIPPGCNLKIFNNQEFAALLAQSVNQGFEAVYQLTRMCTIRMSFVKGWGAEYRRQTVTSTPCWIELHLNGPLQWLDKVLTQMGSPSVRCSSMS

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

SMAD2-Ser118
Cancer Intensity
BRCA
COAD -1.1
HGSC
ccRCC 0.246
GBM
HNSC
LUAD
LUSC 0.854
non_ccRCC
PDAC
UCEC
SMAD2-Thr172
Cancer Intensity
BRCA 0.002
COAD -0.816
HGSC 1.954
ccRCC -0.467
GBM
HNSC -0.115
LUAD -0.6
LUSC 0.334
non_ccRCC -1.011
PDAC -0.765
UCEC 1.485

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 467 U Head and neck squamous cell carcinoma Phosphorylation 21281788 ;  35022323
S 467 U Marfan syndrome Phosphorylation 15731757

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: